| Literature DB >> 31684012 |
Bergthor Traustason1, Matthew Cheeks2, Duygu Dikicioglu3.
Abstract
Chinese hamster ovary (CHO) cells are used for the production of the majority of biopharmaceutical drugs, and thus have remained the standard industry host for the past three decades. The amino acid composition of the medium plays a key role in commercial scale biologics manufacturing, as amino acids constitute the building blocks of both endogenous and heterologous proteins, are involved in metabolic and non-metabolic pathways, and can act as main sources of nitrogen and carbon under certain conditions. As biomanufactured proteins become increasingly complex, the adoption of model-based approaches become ever more popular in complementing the challenging task of medium development. The extensively studied amino acid metabolism is exceptionally suitable for such model-driven analyses, and although still limited in practice, the development of these strategies is gaining attention, particularly in this domain. This paper provides a review of recent efforts. We first provide an overview of the widely adopted practice, and move on to describe the model-driven approaches employed for the improvement and optimization of the external amino acid supply in light of cellular amino acid demand. We conclude by proposing the likely prevalent direction the field is heading towards, providing a critical evaluation of the current state and the future challenges and considerations.Entities:
Keywords: Chinese hamster ovary; amino acid; biologics; biomanufacturing; design of experiments; heterologous expression; medium development; metabolic models
Mesh:
Substances:
Year: 2019 PMID: 31684012 PMCID: PMC6862603 DOI: 10.3390/ijms20215464
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Overview of the mainstream approaches currently used in the optimization of amino acid composition in culture medium for recombinant protein-producing Chinese hamster ovary (CHO) cells. Note that the approaches summarized above are those specifically relevant within the domain of tailoring medium composition for optimal utilization of amino acids within the domain of recombinant protein production by CHO cells. A plethora of alternative systematic strategies not limited to those covered here (beyond the scope of this Review) exist, which deal with different aspects of improving biomanufacturing platforms for CHO cell-based technologies. FBA: flux balance analysis; MFA: metabolic flux analysis; ADP: adenosine diphosphate; ATP: adenosine triphosphate; v: rate of reaction; [S]: substrate concentration; vmax: maximum rate of reaction; KM: saturation constant.
Summary of the available kinetic model-based approaches employed in recombinant protein-producing CHO cell medium development and optimization.
| Details on Kinetic Model | Metabolites/Pathways Involved | Reference |
|---|---|---|
| Monod-kinetics, Luedeking-Piret model for associating rates of growth and product formation | Growth, glucose uptake, lactate secretion, product formation | [ |
| Dynamic model, particle-swarm optimization for parameter estimation | Alanine, glutamine, glutamate, aspartate, asparagine, and proline utilization, product formation | [ |
| 34-reaction model, multiplicative Michaelis-Menten kinetics | Role of amino acids in central carbon metabolism, tricarboxylic acid (TCA) cycle, recombinant monoclonal antibody (mAb) production, and cellular growth | [ |
| Kalman filters for approximating the state variables represented by dynamic mathematical models, model predictive control on the apoptotic cell density, neural networks to express apoptotic cells as a function of state variables | Viable cell density, glutamine and asparagine concentration to predict apoptotic cell population | [ |
Summary of the available stoichiometry-based models employed in recombinant protein-producing CHO cell medium development and optimization.
| Method | Scale | Reference |
|---|---|---|
| Metabolic flux analysis + 13C analysis | Small scale: 272 reactions and 228 metabolites | [ |
| Metabolic flux analysis + 13C analysis | Small scale: 58 reactions and 50 metabolites | [ |
| Elementary flux mode analysis/extreme pathways | Small scale: 24 extracellular, 13 intracellular species, 35 reactions | [ |
| Metabolic flux analysis + 13C analysis | Small scale: 73 reactions and 77 metabolites | [ |
| Metabolic flux analysis + 13/14/15C-labelling | Small scale: 68 reactions and 21 metabolites (19 amino acids) | [ |
| Metabolic flux analysis + 13C-labelled glucose and glutamine | Small scale: 37 reactions | [ |
| Metabolic flux analysis | Small scale: 34 reactions and 30 metabolites | [ |
| Metabolic flux analysis in response to varying levels of glutamine supplementation | Small scale: 40 reactions and 37 intracellular, 23 extracellular metabolites | [ |
| Metabolic flux analysis to modify medium amino acid composition | Small scale: 23 reactions and 23 metabolites | [ |
| Elementary flux mode analysis + kinetic modelling | Small scale: 166 reactions and 29 extracellular, 89 intracellular metabolites | [ |
| Flux balance analysis | Genome scale: 1540 reactions and 1302 metabolites | [ |
| Flux balance analysis | Genome scale: 1766 genes, 6663 reactions, and 4456 metabolites (in different subcellular compartments) | [ |